MNPR-101 is not expected to replace existing therapies, but rather to complement them. Based upon the non-overlapping toxicity and distinct mechanism of action, we plan to develop MNPR-101 in combination with existing cancer therapies to potentially improve treatment outcomes, rather than merely competing with current therapies in the market. The selective expression of uPAR in tumors underpins the expectation that MNPR-101 will be well-tolerated and amenable to a variety of treatment approaches, including combinations with existing treatments, radiopharmaceutical, and antibody-drug conjugate approaches. Published preclinical data have shown the ability of MNPR-101 to enhance the anti-tumor activity of chemotherapies such as paclitaxel and gemcitabine. Our current strategy is to advance MNPR-101 into a Phase 1a/1b trial in indications where uPAR expression is highly prevalent and explore novel combinations, such as with checkpoint Inhibitors or as a radiotherapeutic, in the Phase 1b portion.